Company Overview and News
JAKARTA, May 2 (Reuters) - Indonesian President Joko Widodo on Wednesday slammed state-owned oil firm Pertamina, saying it hadn’t invested enough in exploration, while blasting red tape hobbling the industry and urging investors to report problematic rules to him directly.
JAKARTA (Reuters) - Indonesian President Joko Widodo on Wednesday slammed state-owned oil firm Pertamina, saying it hadn’t invested enough in exploration, while blasting red tape hobbling the industry and urging investors to report problematic rules to him directly.
Lion Energy Limited reports that the Indonesian Amanah Timur discovery well (AMT-1) has been plugged and abandoned following unsuccessful attempts to free a stuck drill pipe.
Lion requested the halt pending an update on the Amanah Timur-1 well, which is located in Indonesia.
The company has lifted a total of 500,235 barrels of crude oil as on 25 December 2016, since the commencement of oil production from the Oseil oilfield.
The halt will remain in place until the opening of trade on Tuesday 6th December 2016, or earlier if an announcement is made to the market.
Lion Energy Ltd (ASX Code: LIO) is pleased to announce it has increased its interest in the South Block A PSC. Lion, in conjunction with Operator REE, have exercised their rights to default PT Prosys Oil & Gas International (POGI). POGI's 14% interest will be taken up pro-rata by Lion and REE, as per the Joint Operating Agreement (JOA) covering the South Block A PSC. As a result of the default, Lion will hold 40.
Lion Energy upgrades proven oil reserves in Seram (Non-Bula) Production Sharing Contract in eastern Indonesia by 28 percent.
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...